{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:32:30Z","timestamp":1793298750378,"version":"4.5.0"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Urology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA) PET is becoming the preferred imaging technique for prostate cancer (PCa) because of its superior sensitivity and specificity compared to traditional imaging methods. This article evaluates the methodological and reporting quality of literature regarding the cost-effectiveness of PSMA-positron emission tomography (PET)\/computed tomography (CT) or MRI for detecting and staging PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the methodological and reporting quality of the published cost-effectiveness studies on PSMA-PET.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>MEDLINE and EMBASE were searched from inception to December 05, 2025. Two researchers independently screened all retrieved articles according to inclusion and exclusion criteria. Studies were appraised for methodological quality using the Quality of Health Economic Studies checklist and for reporting quality using the Consolidated Health Economic Evaluation Reporting Standards checklist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of seven studies were examined, representing both private and public healthcare systems. Overall, these studies demonstrate high methodological and reporting quality. When compared to existing imaging technologies or standard care practices, PSMA-PET\/CT or MRI is cost-effective within country-specific willingness-to-pay thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Cost-effectiveness evaluations may not be widely generalizable due to significant variability among geographical regions concerning resource availability, costs, morbidity and mortality, and standards of practice. As PSMA-PET\/CT imaging technology becomes more widely available in additional countries in the coming years, we expect to generate more country-specific data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562872261436874","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T05:29:10Z","timestamp":1774848550000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of PSMA-PET imaging technology in diagnosing and staging of prostate cancer: a systematic review"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3677-8036","authenticated-orcid":false,"given":"Chiranjeev","family":"Sanyal","sequence":"first","affiliation":[{"name":"College of Pharmacy, Faculty of Health, Dalhousie University, 5968 College St, Halifax, NS B3H 4R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rendon","sequence":"additional","affiliation":[{"name":"Department of Urology, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_4_3_2","article-title":"Projected estimates of cancer in Canada in 2024","volume":"196","author":"Brenner DR","year":"2024","unstructured":"Brenner DR, Gillis J, Demers AA, et al. Projected estimates of cancer in Canada in 2024. CMAJ Can Med Assoc J J Assoc Medicale Can 2024; 196: E615\u2013E623.","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"key":"e_1_3_4_4_2","unstructured":"Survival Rates for Prostate Cancer https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html (accessed on 16 October 2025)."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.18475"},{"key":"e_1_3_4_6_2","article-title":"Management of prostate cancer in older adults","volume":"43","author":"Graham LS","year":"2023","unstructured":"Graham LS, Lin JK, Lage DE, et al. Management of prostate cancer in older adults. Am Soc Clin Oncol Educ Book 2023; 43: e390396.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112594"},{"key":"e_1_3_4_8_2","unstructured":"Pharmacoeconomic Guidelines Around the World https:\/\/www.ispor.org\/heor-resources\/more-heor-resources\/pharmacoeconomic-guidelines (accessed on 16 October 2025)."},{"key":"e_1_3_4_9_2","unstructured":"2020-2023 Value Assessment Framework. Institute for Clinical and Economic Review USA https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf (accessed on 16 October 2025)."},{"key":"e_1_3_4_10_2","unstructured":"Guidelines for the economic evaluation of health technologies: Canada. 4th edition. Appendix \u2013 Worked Example https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/economic_guidelines_worked_example.pdf (accessed on 16 October 2025)."},{"key":"e_1_3_4_11_2","unstructured":"Office for Health Improvement and Disparities. Cost utility analysis: health economic studies https:\/\/www.gov.uk\/guidance\/cost-utility-analysis-health-economic-studies (accessed on 16 October 2025)."},{"key":"e_1_3_4_12_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-020-10027-1"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01156-4"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35567-w"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01322-2"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.02.013"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.043"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-022-01265-w"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780192896087.003.0022"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200301000-00007"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2003.9.1.53"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00255.x"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07190-6"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.39250"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35474"}],"container-title":["Therapeutic Advances in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562872261436874","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562872261436874","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562872261436874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:46:16Z","timestamp":1775094376000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562872261436874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"alternative-id":["10.1177\/17562872261436874"],"URL":"https:\/\/doi.org\/10.1177\/17562872261436874","relation":{},"ISSN":["1756-2872","1756-2880"],"issn-type":[{"value":"1756-2872","type":"print"},{"value":"1756-2880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"17562872261436874"}}